AcquisitionsJun 1, 2026, 04:05 PM
Resmed Completes Acquisition of Noctrix Health
AI Summary
Resmed announced the completion of its acquisition of Noctrix Health, Inc., a medical device company specializing in wearable therapeutics for chronic neurological disorders. This strategic move expands Resmed's clinical sleep health portfolio to include the treatment of Restless Legs Syndrome (RLS), a significant unmet need. Noctrix's Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified non-invasive treatment, is designed to alleviate RLS symptoms and enhance sleep quality. The acquisition aligns with Resmed's 2030 strategy to scale solutions that improve lives through better sleep and home health technologies.
Key Highlights
- Resmed completed the acquisition of Noctrix Health, Inc.
- Noctrix Health develops clinically validated wearable therapeutics for chronic neurological disorders.
- The acquisition expands Resmed's portfolio into treating Restless Legs Syndrome (RLS).
- Noctrix's Nidra® TOMAC Therapy is an FDA De Novo classified, non-invasive treatment for RLS.
- The therapy is designed to reduce RLS symptoms and improve sleep quality in adults.
- Noctrix has 10 peer-reviewed publications and inclusion in AASM clinical practice guidelines.
- Resmed plans to integrate Noctrix's technology to expand access and improve patient outcomes.
- The acquisition advances Resmed's 2030 strategy for clinical sleep health.
- Noctrix Health became a wholly owned subsidiary of Resmed.
- The acquisition was previously announced on April 30, 2026, during Resmed's Q3 FY26 earnings call.
Price Impact
More from RMD